title: Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
authors.forename: Ceyla
authors.initials: C
authors.lastname: Konca Degertekin
authors.forename: Uğur
authors.initials: U
authors.lastname: Coşkun
authors.forename: Füsun
authors.initials: F
authors.lastname: Baloş Törüner
authors.forename: Müjde
authors.initials: M
authors.lastname: Aktürk
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced*; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D000077157:Sorafenib; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000000981:diagnostic imaging; D013967:Thyroiditis, Autoimmune / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib